Physician profile
Kathrin Dvir
NPI 1417441163
$4,780.51
in general payments reported to CMS, 2019-2025
9 companies · $4,430 in 2025
The $4,430 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.95 · 2023: $61.99 · 2024: $254 · 2025: $4,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,480 · Food and Beverage: $1,205 · Education: $61.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,480.00 |
| Food and Beverage | $1,204.57 |
| Education | $61.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $2,187.49 | 2025 | Itovebi |
| Lilly USA, LLC | $1,828.85 | 2025 | Verzenio |
| Astrazeneca Pharmaceuticals LP | $252.29 | 2024-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $174.02 | 2019-2025 | |
| Stemline Therapeutics INC. | $142.36 | 2024-2025 | Orserdu |
| Pfizer INC. | $63.49 | 2025 | |
| Astellas Pharma US INC | $61.99 | 2023 | |
| Novartis Pharmaceuticals Corporation | $56.06 | 2025 | |
| Amneal Pharmaceuticals LLC | $13.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathrin Dvir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.